Overview

IDH1 (AG 120) Inhibitor in Patients With IDH1 Mutated Myelodysplastic Syndrome

Status:
Recruiting
Trial end date:
2025-04-02
Target enrollment:
Participant gender:
Summary
patients with MDS (Myelodysplastic Syndrome) and mutated IDH1 patients will be treated with AG120 (IDH1 inhibitor)
Phase:
Phase 2
Details
Lead Sponsor:
Groupe Francophone des Myelodysplasies
Treatments:
Ivosidenib